Welcome to Last Minute Lecture.
This free chapter overview is designed to help students review and understand key concepts.
These summaries supplement not replaced the original textbook and may not be redistributed or resold.
For complete coverage, always consult the official text.
Welcome back to the Deep Dive.
Today we're tackling something really intricate,
high stakes even, how we manage the heart's electrical system when it starts acting up.
We're going deep into anti -dysrhythmic drugs using only chapter 27 from Lilly's Pharmacology as our guide.
Our mission today is to get comfortable with cardiac electrophysiology, you know, the basics, so we can understand the four main drug classes used to, well, fix a faulty rhythm.
Right, and maybe first let's clear up some terms for you.
You'll hear arrhythmia and dysrhythmia.
Now technically arrhythmia means no rhythm, like a systole.
Dysrhythmia just means an abnormal rhythm.
Lilly's prefers dysrhythmia, but honestly, in practice, you hear them used pretty much interchangeably.
Okay, dysrhythmia, yes it is.
So before we get to the drugs themselves, we need that foundation, the heart's electrical sequence.
What do we absolutely need to know?
It all comes down to the action potential.
That's the cycle of electrical change across the heart cell membrane.
It's all about ions moving in and out.
So at rest, the inside of that's the resting membrane potential, or RMP, kept stable by the good old sodium potassium pump.
Okay, negative at rest, then it gets triggered.
Walk us through the phases
focusing on what the drugs target.
Okay, so phase zero is the big kickoff.
Depolarization, think of fast sodium ions just flooding into the cell, makes it positive real quick.
Sodium in, fast, got it.
And that steepness, how fast it happens, that affects conduction speed.
Class I drugs, they mess with this phase.
Right, then what?
Then you hit phase two, the plateau, it's slower.
Here, it's calcium ions moving in through slower channels.
Super important for the SA and AV nodes.
Ah, the pacemakers.
And class four drugs target this.
Exactly.
Then phase three is repolarization, potassium ions flow out, making the cell negative again, resetting things.
Potassium out, class three drugs work here.
You got it.
And phase four is just back to that resting negative state.
So the whole cycle is the action potential duration, or APD.
And during part of that cycle, the cell can't fire again, right?
The refractory period.
Precisely.
The effect of refractory period ERP.
It's a crucial safety pause.
Then a relative refractory period, RRP, where only a strong signal could trigger it.
Makes sense.
You also mentioned pacemakers.
Some cells just fire on their own, automaticity.
Yep.
The SA node is usually the boss, firing at 60 or 100 beats per minute.
If it fails, the AV node can step in, slower though, 40, 60.
And if that fails, the Purkinje fibers try, but they're even slower, like 40 or less.
It's a backup system.
And all this electrical activity creates the ECG trace we see.
P wave, QRS, T wave.
That's right.
P wave is atrial depolarization, QRS is the ventricles firing, T wave is them repolarizing.
And drug effects or disease often show up as changes in those intervals, like the PR or QT interval.
Okay.
So when this system glitches, we get dysrhythmias.
You mentioned they're classified by location.
Superventricular or ventricular?
Correct.
Superventricular means it originates above the ventricles.
SA node, atria, AV node.
Ventricular means below the AV node.
And one really common, really critical superventricular one is atrial fibrillation, AFIV.
Oh, absolutely.
AFIV is incredibly common.
The atria are basically just quivering, contracting super fast, but not effectively pumping blood down to the ventricles.
Just quivering.
So the blood just sits there.
What's the big risk?
Stroke.
Huge risk.
That stagnant blood pools and forms clots in the atria.
If one breaks loose, travels to the brain.
Stroke.
Wow.
That 4 .5 % annual risk the book mentions suddenly sounds terrifyingly high.
It is.
That's why anticoagulation warfarin, or the newer ones like apixaban, is almost always part of AFIV management, alongside trying to control the rhythm or rate.
Okay, that's super ventricular.
What about when the trouble starts in the ventricles?
Sounds even scarier.
It generally is.
You can start with things like premature ventricular contractions, PVCs, coming from irritable spots in the ventricle.
And those can escalate?
They sure can.
Too many PVCs, or runs of them, can lead to ventricular tachycardia, or VT.
That's a fast, dangerous rhythm.
And VT can worsen into something called torsades de pointe.
It looks like a twisted ribbon on the ECG.
Very distinctive.
Often linked to QT prolongation.
Torsades.
Sounds bad.
What happens next?
If torsades isn't treated sometimes.
IV magnesium sulfate helps specifically with this one.
It can degenerate into ventricular fibrillation, VF.
And VF is lethal.
The ventricles are just quivering chaotically.
No blood is being pumped.
Needs immediate defibrillation and electric shock to have any chance of survival.
Okay, understanding the danger makes the drug seem even more crucial.
Let's get into them.
The Vaughan Williams classification is a standard way to group them.
It is.
It groups them based on how they affect that action potential we talked about.
What part of the cycle they target.
So class I first.
The sodium channel blockers.
Affecting phase zero depolarization.
Right.
But they're split into three subclasses.
Ea, Eb, and Ike, based on how they also affect repolarization phase three.
Okay, tell us about Ea.
Quinidine.
Procanamide.
Class I drugs block sodium channels and they delay repolarization, making the action potential longer.
But they have significant risks you need to know.
Procanamide.
Long -term use can cause an SLE -like syndrome in up to 30 % of patients.
Wow, like lupus.
Yeah, drug -induced lupus.
And quinidine can cause synchronism.
That's a cluster of symptoms.
Tinnitus, blurred vision, GI issues.
Okay, notable risks.
What about class Ib?
Lidocaine is the big one here.
Yes, lidocaine.
Class Ib agents block sodium channels, but they accelerate repolarization.
They shorten the action potential duration.
Lidocaine is great for ventricular dysrhythmias.
It raises the ventricular fibrillation threshold, making VF less likely.
But you mentioned it's IV only for cardiac use.
Absolutely.
It gets broken down so heavily by the liver on the first pass, oral doses just won't work effectively for the heart.
IVV is the only way.
Got it.
Then class I'd.
Fleconide, bropaphenone.
These have the most potent sodium channel blocking effect, but they really don't change repolarization much.
Fleconide.
Well, there was that CAS -T trial years ago that made people nervous about using it after a heart attack.
Right, I remember reading about that controversy.
Yeah, but guidelines have evolved.
Now, it's actually often a first -line choice for AFib, provided the patient doesn't have structural heart disease, usually used with another drug to control the AV node too.
Okay, that covers class I, the sodium blockers.
What about when the problem is too much adrenaline, too much sympathetic drive?
Class II.
That's where the beta blockers come in.
Metaprol, Atenolol are common examples.
Class II drugs block those beta receptors on the heart.
They mainly work by depressing that spontaneous firing in phase IV, slowing the heart rate down.
And the big plus for them.
Their cardioprotective effect, especially after a heart attack, they've been shown to significantly reduce the risk of sudden cardiac death.
We should also mention Esmolol.
It's an IV beta blocker that's ultra short -acting, so you can adjust the dose really quickly in critical situations.
Makes sense.
Okay, onto class III, the ones that prolong repolarization.
Exactly.
They work primarily in phase III, blocking potassium channels to increase the action potential duration,
increase that refractory period.
Think amiodarone, Sotalol.
These are often used for tougher dysrhythmias, ones that haven't responded to other drugs.
Sotalol is interesting because it actually has both class II beta blocking and class III potassium blocking effects.
Dual action.
Okay, and finally, class IV.
Class IV are the non -dihydropyridine calcium channel blockers for rapamil and biltiasum.
And they target.
They inhibit those slow calcium channels,
mainly affecting phase II, the plateau.
This really slows down conduction through the AV node and depresses phase IV in the SA and AV nodes.
So their use is pretty specific.
Very specific, primarily for superventricular tachycardias, like PSVT, or to slow down the ventricular rate when someone's an AFib or atrial flutter.
They act like brakes on the AV node.
Okay.
We've got the four classes mapped out, but you mentioned something crucial earlier, a shared danger.
Yes.
The paradox.
All antidisrhythmic drugs can also cause dysrhythmias.
It's called the prodisrhythmic effect.
So the cure can be the cause.
Potentially, yes.
It's a huge concern.
One major mechanism is prolonging the QT interval on the ECG, which increases the risk for that dangerous torsade de pointe rhythm.
High stakes indeed.
And speaking of high risk, let's talk about emuderone.
It's class III, but it seems to have its own whole section of warnings.
Why is it so tricky?
Emuderone is.
Well, it's incredibly effective for many difficult dysrhythmias, both atrial and ventricular.
But its chemistry is the problem.
It's highly lipophilic.
Lipophilic, meaning?
Meaning it loves fat.
It dissolves readily in fatty tissues and accumulates their liver, lungs, thyroid, skin, even the eyes.
It stays in the body for a very, very long time.
And that accumulation leads to serious side effects.
Very serious.
Pulmonary toxicity is the most feared.
It can cause irreversible lung damage, fibrosis, and can be fatal in about 10 % of cases.
It can also mess with the thyroid, causing either hyper or hypothyroidism.
Causes corneal microdeposits, tiny specks in the eye that can cause visual halos.
And that skin discoloration.
Yes, that distinctive blue -gray discoloration on sun -exposed areas like the face and arms.
It happens with long -term use.
And because it sticks around so long,
its half -life is incredibly long.
How long?
Weeks to months.
It can take 2 -3 months after stopping the drug for its effects and side effects to really diminish.
Wow.
And does this accumulation affect other drugs too?
Interactions?
Oh, big time.
The interaction with warfarin and digoxin is critical.
If you start amiodarone in a patient on warfarin, their INR is likely to shoot up by 50 % almost guaranteed.
So major bleeding risk.
Huge risk.
You must anticipate this and cut the warfarin dose, usually by about half, when starting amiodarone.
Same for digoxin levels can increase by 50%, risking toxicity.
Dose reduction is essential.
Any food interactions we need to flag?
Yes.
Grapefruit juice.
It inhibits the enzyme system that breaks down several antidiarrhythmias, including amiodarone, quinadine, and disapiramide.
So drinking grapefruit juice could lead to toxic levels of the drug?
Absolutely.
Patients on these drugs need to avoid grapefruit juice entirely.
Okay, one more drug to touch on that doesn't fit neatly into the classes, adenosine.
Ah, adenosine.
Unique stuff.
It's used primarily to stop superventricular tachycardia, specifically PSVT, and let the normal sinus rhythm hopefully take over.
How does it work so fast?
Its half -life is ridiculously short, less than 10 seconds.
It has to be given as a very rapid IV push, followed immediately by a saline flush.
And what happens when you push it?
It very effectively slows conduction through the AV node,
so effectively that it commonly causes a few seconds of a systole.
No heartbeat at all, for a few seconds.
Yep.
Looks dramatic on the monitor, but it's expected.
Then ideally, the heart resets into a normal rhythm.
Definitely needs cardiac monitoring.
Definitely.
Okay, let's shift to nursing practice.
What are the absolute must -do assessments before starting any of these drugs?
Baseline, baseline, baseline.
Get a full set of vital signs, pay close attention to heart rate, making sure it's not already too low, say below 60 or too high, maybe over 100.
Systolic blood pressure needs to be adequate, usually above 90 mmHg.
Get a baseline ECG to know what their rhythm looks like before the drug.
And check labs electrolytes like potassium and magnesium are crucial, plus kidney and liver function tests, because poor function can lead to drug accumulation.
Makes sense.
Any specific administration cautions?
You mentioned lidocaine earlier.
Yes, with lidocaine, double, triple check the vial.
Make sure you're using the solution without epinephrine for IV cardiac use.
Epinephrine is for local anesthesia, adding it, IV would be catastrophic.
Good point.
And IV administration generally?
Always use an infusion pump for continuous IV drips of these drugs.
Precision is key.
And for oral doses, taking them with food or milk can help minimize GI upset, which is pretty common.
Okay, now for patient teaching.
This seems critical given the risks.
What do patients absolutely need to know?
First, if they're on a sustained release tablet, they might see something that looks like the pill in their stool.
It's usually just the empty wax matrix after the drug has been absorbed.
Re -sure them about that.
Okay, what else?
Orthostatic hypotension is a risk with many of these.
Teach them to change positions,
slowly sit up, dangle their legs, then stand to avoid dizziness or falls.
And the number one rule, never stop taking these medications abruptly without talking to their prescriber.
Suddenly stopping can cause rebound dysrhythmias, some potentially fatal.
Huge point.
What about amiodarone specifically?
Extra instructions?
Definitely.
Because of the photosensitivity, they need strict sun avoidance.
Wear protective clothing,
hats, use strong sunscreen even on cloudy days, and they need to report any signs of trouble immediately.
Shortness of breath, cough, could be lung toxicity, visual changes, any yellowing of the skin or eyes, jaundice, suggesting liver issues, or that blue -gray skin discoloration.
It really highlights how this therapy is a constant balancing act, doesn't it?
Trying to fix one rhythm problem without causing another.
That's the essence of it.
That pro -dysrhythmic potential looms over everything.
It's why managing conditions like AFib is becoming more complex.
Like the book notes, we're often combining these drugs with procedures now catheter ablation to electrically isolate problem areas, or pacemaker implantation, especially in older adults where drug side effects are more problematic.
Which leads to a final thought for you to consider.
Given the really significant systemic side effects we see with drugs like amiodarone, the lung toxicity, the thyroid issues, how much further might cardiac device therapy evolve?
Could things like advanced pacemakers or ablation techniques eventually push purely pharmacological rhythm control into a secondary role, especially for chronic conditions?
It's sort of a chemistry versus engineering question for the future.
It's a fascinating question.
Thank you for joining us on this deep dive into anti -dysrhythmic pharmacology based on Lilly's.
We really hope breaking down this complex chapter helps you feel more confident with these critical medications.